On March 24, Lisheng Pharmaceutical) announced its 2025 annual report. The company's operating income was 1.39 billion yuan, a year-on-year increase of 4.2%; net profit attributable to shareholders was 416 million yuan, a year-on-year increase of 125.6%; Net profit after deducting non-attributable shares was 169 million yuan, a year-on-year increase of 63.6%; net operating cash flow was 247 million yuan, a year-on-year increase of 180.4%; EPS (fully diluted) was 1.6159 yuan.
In the fourth quarter, the company's operating income was 385 million yuan, a year-on-year increase of 23.2%; net profit attributable to the parent company was 45.54 million yuan, a year-on-year increase of 198.1%; net profit after non-attribution to the parent company was successfully reversed from a loss of 3.31 million yuan in the same period last year, and net profit after non-attribution to the parent company was 41.8 million yuan; EPS was 0.1768 yuan.
As of the end of the fourth quarter, the company's total assets were 5.584 billion yuan, down 3.5% from the end of the previous year; net assets attributable to the parent company were 4.628 billion yuan, down 3.0% from the end of the previous year.
The announcement mentioned that during the reporting period, the company focused on core technology and product research and development, focusing on key areas such as synthetic biology and improved new drugs, and completed the establishment of 11 new projects, including 2 improved innovative drugs, filling the gaps; throughout the year, it completed 36 patent applications and 14 patent authorizations, promoted 19 product document applications, and 10 were approved, and continued to enrich the research and development pipeline and enhance the core competitiveness of products.
At the same time, we deepened collaborative innovation and achievement transformation, signed a strategic cooperation agreement with Tianjin University of Science and Technology, launched joint research on drug eutectic projects, integrated university scientific research resources to make up for internal research and development shortcomings; established a research, production and sales linkage mechanism to incorporate opinions from the market and production links from the project establishment stage to ensure that research and development results meet market demand, significantly improve transformation efficiency, and promote the rapid implementation of research and development results into operating benefits.
(Announcement from Lisheng Pharmaceutical)
